Governance of polycystic ovary syndrome (PCOS / PMOS) care spans primary care, gynaecology, endocrinology, dermatology and fertility services.
National guidance from NICE provides the core framework for diagnosis and management, yet implementation shows significant variation across regions.
Evidence from patient surveys and parliamentary inquiry highlights prolonged diagnostic delays, with a substantial proportion of women waiting more than four years. Post-diagnosis support is often limited, and metabolic risk monitoring is inconsistently coded or followed when women move between services. The lack of dedicated primary care guidance has contributed to a postcode lottery in access and quality of care.
Policy developments through the renewed Women’s Health Strategy emphasise improved access, professional training, and the development of Women’s Health Hubs to deliver more joined-up care for conditions including PCOS. These initiatives aim to shift services toward primary and community settings and reduce fragmentation. A new NICE guideline on the condition (under the working name polyendocrine metabolic ovarian syndrome) is in development, with draft expected in 2026.
Maternity governance recognises elevated risks during pregnancy, yet consistent long-term follow-up after gestational diabetes or hypertensive disorders remains patchy for women with PCOS. Broader system challenges include under-representation of certain groups in research and the need for clearer digital triage pathways for chronic hormonal presentations.
Opportunities for improvement lie in standardised coding of metabolic risks, clearer referral protocols between services, inclusive research, and system design that supports longitudinal rather than episodic care.
Related pages on this site
References
- All-Party Parliamentary Group on PCOS. Breaking the Cycle: Addressing Systemic Failures in PCOS Diagnosis and Management (2025).
- NHS England. Women’s Health Strategy for England (renewed).
- National Institute for Health and Care Excellence. Current and developing guidance on PCOS/PMOS.
- International evidence-based guideline for the assessment and management of PCOS (2023).
- Verity PCOS patient survey data (2025).
Mandatory disclaimer This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed. This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.